Chemotherapy Induced Neutropenia Cin Market

DelveInsight’s ‘Chemotherapy Induced Neutropenia (CIN) Market Insights, Epidemiology, and Market Forecast–2030’ report delivers an in-depth understanding of the CIN, historical and forecasted epidemiology as well as the CIN market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.


The CIN market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CIN market size from 2018 to 2030. The Report also covers current CIN treatment practice, market drivers, market barriers, SWOT analysis, reimbursement and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Chemotherapy Induced Neutropenia (CIN) Disease Understanding and Treatment Algorithm

Chemotherapy Induced Neutropenia (CIN) Overview

Chemotherapy-Induced Neutropenia (CIN) is the primary dose-limiting toxicity in patients with cancer treated with chemotherapy. It can lead to febrile neutropenia (FN), and it is associated with increased morbidity and early mortality, increased medical costs, and disruptions in potentially curative treatments. The symptoms of CIN that most patients observe are chills or sweating, Sore throat, sores in the mouth, or a toothache, abdominal pain, pain near the anus, and others.


Chemotherapy Induced Neutropenia (CIN) Diagnosis

The initial evaluation of a patient with CIN includes medical history, initial physical assessments, urinalysis, sputum, stool cultures, laboratory tests—including complete blood cell counts with differential leukocyte and platelet counts—are needed to determine ANC and neutropenia severity.

Continued in the report…..


Chemotherapy Induced Neutropenia (CIN) Treatment

The management of CIN involves two main strategies: modification of the chemotherapy regimen and/or the use of growth factors. The optimal strategy for the management of CIN is prevention. In the management of CIN, myeloid growth factors (MGFs), including G-CSF and granulocyte macrophage-colony stimulating factor (GM-CSF), are used in clinical practice to reduce the risk of febrile neutropenia (FN) and its complications. Currently, there are four recombinant G-CSF formulations: filgrastim (nonglycosylated), lenograstim (glycosylated), pegfilgrastim (filgrastim in pegylated version), and lipefilgrastim (filgrastim in glycosylate version). Biosimilar versions exist for filgrastim and pegfilgrastim. The pegylated version differs for the different plasma half-life, much longer than the non-pegylated version (3–4 h), and allows a single administration of the drug per chemotherapy cycle.

Continued in the report…..

Chemotherapy Induced Neutropenia (CIN) Epidemiology  

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by the Total number of patients on chemotherapy, Risk-specific chemotherapy patient pool for CIN, and Total incident cases of CIN by cancer type scenario in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.


Key Findings

  • In the 7MM, the total estimated number of cancer patients on chemotherapy was 1,790,618 in 2020.
  • In 2020, the highest number of cancer patients on chemotherapy were accounted by the US making up to 691,906, while the EU5 countries accounted for 778,973 number of cancer patients on chemotherapy. Japan ranked second among 7MM countries with 319,740 cancer patients on chemotherapy in 2020.
  • Assessments as per DelveInsight show that there were 484,334 cases at intermediate-high risk for CIN, and 207,572 cases at low risk for CIN in the United States, in 2020.
  • In 2020, the total number of cases of CIN in the 7MM was 903,597. The US accounted for a majority of cases in the 7MM with 383,339 cases.
  • The CIN cases are included from various cancers such as breast, lung, ovarian, AML, lymphoma, and other cancers. Out of all cancers, in 2020, the highest CIN cases was from breast cancer i.e. 99,944 cases. Furthermore, 2,354 CIN cases in AML were the lowest among all cancers, in the US.
  • Among the European countries, Germany had the highest cases of CIN with 96,877 cases, followed by the UK which had 78,494 cases of CIN in 2020. On the other hand, Spain had the lowest number of CIN cases in 2020, i.e. 46,167.
  • In 2020, Japan accounted for 153,260 cases of CIN, which is second-highest after the US among 7MM countries.

Country Wise Chemotherapy Induced Neutropenia (CIN) Epidemiology

The epidemiology segment also provides the Chemotherapy Induced Neutropenia (CIN) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Chemotherapy Induced Neutropenia (CIN) Drug Chapters

The drug chapter segment of the Chemotherapy Induced Neutropenia (CIN) report encloses the detailed analysis of Chemotherapy Induced Neutropenia (CIN) marketed drugs, mid-phase, and late-stage pipeline drugs. It also helps to understand the Chemotherapy Induced Neutropenia (CIN) clinical trial details, expressive pharmacological action, agreements and collaborations, approval, and patent details of each included drug and the latest news and press releases.


Chemotherapy Induced Neutropenia (CIN) Marketed Drugs


Neupogen (Filgrastim): Amgen

Neupogen (Filgrastim) is a human granulocyte colony-stimulating factor (G-CSF). Neupogen is a leukocyte growth factor indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever. Neupogen is a recombinant methionyl human granulocyte colony-stimulating factor (r-metHuG-CSF). Neupogen is a 175 amino acid protein manufactured by recombinant DNA technology which is produced by inserting the human granulocyte colony-stimulating factor gene into Escherichia coli bacteria.

Products detail in the report…


Neulasta (pegfilgrastim): Amgen/Kyowa Hakko Kirin Co., Ltd.

Neulasta (pegfilgrastim) is a colony-stimulating factor, a man-made form of a protein that stimulates the growth of white blood cells, used to decrease the incidence of infection, by treating neutropenia, a lack of certain white blood cells caused by receiving cancer chemotherapy. Neulasta (pegfilgrastim) is a covalent conjugate of recombinant methionyl human G CSF (filgrastim) and monomethoxypolyethylene glycol. It is a leukocyte growth factor indicated to


  • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
  • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Sub syndrome of Acute Radiation Syndrome).


Products detail in the report…

List to be continued in the report…


Chemotherapy Induced Neutropenia (CIN) Emerging Drugs


EC-18: Enzychem Lifesciences Corporation

Enzychem Lifesciences is developing a novel small molecule therapy to target fundamental pathways in inflammation, patients with significant unmet needs in oncology, inflammatory, and severe respiratory diseases. Based on more than two decades of research, the company has developed their leading candidate EC-18 (Mosedipimod)—an oral small molecule derived from Sika deer antler—which has shown to be active across a number of different indications. Currently, mosedipimod is being investigated against chemoradiation-induced oral mucositis and neutropenia, as well as against COVID-19.

Products detail in the report…


Plinabulin: BeyondSpring Pharmaceuticals

Plinabulin is a novel small molecule that is being developed for the mitigation of chemotherapy-induced neutropenia. Administered by intravenous infusion on the same day of (approximately 1 hour after) chemotherapy (TAC), plinabulin will be given in a single dose per cycle. The drug is a differentiated immune and stem cell modulator. Plinabulin is currently in late-stage clinical development to increase overall survival in cancer patients, as well as to alleviate CIN. The durable anticancer benefits of the drug have been associated with its effect as a potent antigen-presenting cell (APC) inducer (through dendritic cell maturation) and T-cell activation.

Products detail in the report…

List to be continued in the report…

Chemotherapy Induced Neutropenia (CIN) Market Outlook

United States contributes to the major share of the Chemotherapy Induced Neutropenia (CIN) market as compared to other 7MM countries.

The optimal strategy for the management of CIN is prevention. Neutropenia can be avoided or ameliorated by giving less chemotherapy or by stimulating marrow recovery as soon as possible after the chemotherapy, using the colony-stimulating factor (CSFs).


Treatment is required when neutropenia is associated with fever because the body may not be able to effectively fight an active infection that occurs during this time. Hospitalization is advisable for the majority of patients with FN. Broad-spectrum antibiotics are quickly initiated, and the patient is observed until the neutrophil count recovers. In the management of CIN, myeloid growth factors (MGFs), including G-CSF and granulocyte macrophage-colony stimulating factor (GM-CSF), are approved for clinical practice to reduce the FN risk and its complications.


American Society of Clinical Oncology (ASCO) guidelines recommends primary prophylaxis, or first cycle use, with CSFs being confined to patients with a ≥40% risk of FN, which may include elderly patients and other high-risk patients. In addition to the risk of FN, primary prophylaxis is considered if the patient has risk factors that place them in the Special Circumstances category. These risk factors may include decreased immune function in patients already at an increased risk of infection and pre-existing neutropenia due to disease, extensive prior chemotherapy, or previous irradiation to the pelvis or other areas containing large amounts of bone marrow.


There are several significant limitations to using CSFs in cancer chemotherapy. The cost of these agents is extremely high; therefore, pharmaco-economic evaluations must show that their use can offset other costs, i.e. hospital costs, for the CSFs to prove themselves as having a cost-benefit. Thus, the price of a hospital day, including antibiotics plus other costs, must be balanced against increased drug costs. One of the most important consequences of using CSFs may be an improvement in patient quality of life. Unfortunately, this has not been extensively studied. Further investigation is necessary to determine the positive benefits associated with the use of CSFs.


Key Findings

  • The therapeutic market of CIN in the 7MM was USD 5,128 million in 2020.
  • The therapeutic market of CIN in the United States was USD 3,567 million in the year 2020.
  • The current market of Chemotherapy Induced Neutropenia (CIN) is mainly covered by Neulasta, Neupogen, and their biosimilars. The market size of Neupogen and Neulasta was USD 216 million and USD 2,450 million, respectively in 2020.
  • The market size in the 7MM might increase at a CAGR of 1.76%. An increase in the incidence of cancer, current and emerging chemotherapy treatment of cancer leading to neutropenia progression, are the primary factors driving the growth of the CIN market.
  • The market size of Neupogen and Neulasta is expected to further decline due to the expected launch of new therapies and availability of biosimilars of both these therapies.
  • Rolontis (Spectrum Pharmaceuticals), Plinabulin (BeyondSpring Pharmaceuticals), and F-627 (Evive Biotech)—pipeline candidates—are expected to enter the market in the forecasted period (2021–2030). Cosela (trilaciclib) is approved by the US FDA in February 2021.
  • The therapeutic market of CIN in Japan was USD 504 million in the year 2020.


The United States Market Outlook

This section provides the total Chemotherapy Induced Neutropenia (CIN) market size and; market size by therapies in the United States.


EU-5 Market Outlook

The total Chemotherapy Induced Neutropenia (CIN) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total Chemotherapy Induced Neutropenia (CIN) market size and market size by therapies in Japan are provided.

Chemotherapy Induced Neutropenia (CIN) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched in the CIN market or expected to get launched in the market during the study period 2018–2030. The analysis covers CIN market uptake by drugs; patient uptake by therapies; and sales of each drug.  


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chemotherapy Induced Neutropenia (CIN) Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for Chemotherapy Induced Neutropenia (CIN) emerging therapies.

Reimbursement Scenario in Chemotherapy Induced Neutropenia (CIN)

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the Chemotherapy Induced Neutropenia (CIN) market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 

Scope of the Report

  • The report covers the descriptive overview of CIN, explaining risk factors, symptoms, pathophysiology, biomarkers, diagnosis, and available therapies.
  • Comprehensive insight has been provided into the CIN epidemiology and treatment.
  • Additionally, an all-inclusive account of both the current and emerging therapies for CIN is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
  • A detailed review of the CIN market; historical and forecasted is included in the report, covering the 7MM drug outreach.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM CIN market.

Report Highlights

  • The robust pipeline with novel MOA and oral ROA and increasing incidence will positively drive the CIN market.
  • The companies and academics are working to assess challenges and seek opportunities that could influence CIN R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for CIN. The launch of emerging therapies will significantly impact the CIN market.
  • Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Chemotherapy Induced Neutropenia (CIN) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • CIN Pipeline Analysis
  • CIN Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Chemotherapy Induced Neutropenia (CIN) Report Key Strengths

  • 10-Years Forecast
  • 7MM Coverage
  • CIN Epidemiology Segmentation
  • Key Cross Competition
  • Highly Analyzed Market
  • Drugs Uptake

Chemotherapy Induced Neutropenia (CIN) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers
  • SWOT analysis

Key Questions

Market Insights:

  • What was the CIN market share (%) distribution in 2018 and how it would look like in 2030?
  • What would be the CIN total market size as well as market size by therapies across the 7MM during the forecast period (2021–2030)?
  • What are the key findings pertaining to the market across the 7MM and which country will have the largest CIN market size during the forecast period (2021–2030)?
  • At what CAGR, the CIN market is expected to grow at the 7MM level during the forecast period (2021–2030)?
  • What would be the CIN market outlook across the 7MM during the forecast period (2021–2030)?
  • What would be the CIN market growth till 2030 and what will be the resultant market size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?


Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of CIN?
  • What is the historical CIN patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of CIN at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to CIN?
  • Out of the above-mentioned countries, which country would have the highest incident population of CIN during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?


Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of CIN along with the approved therapy?
  • What are the current treatment guidelines for the treatment of CIN in the US and Europe?
  • What are the CIN marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of CIN?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of CIN?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CIN therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for CIN and their status?
  • What are the key designations that have been granted for the emerging therapies for CIN?
  • What are the 7MM historical and forecasted market of CIN?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the CIN.
  • To understand the future market competition in the CIN market and an insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for CIN in the US, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the CIN market.
  • To understand the future market competition in the CIN market.

1. Key Insights

2. Report Introduction

3. Chemotherapy Induced Neutropenia (CIN) Market Overview at a Glance

3.1. Market Share (%) Distribution of Chemotherapy Induced Neutropenia (CIN) in 2018

3.2. Market Share (%) Distribution of Chemotherapy Induced Neutropenia (CIN) in 2030

4. Executive Summary of Chemotherapy Induced Neutropenia (CIN)

5. Disease Background and Overview

5.1. Introduction

5.1.1. Levels of Neutropenia

5.2. Risk Factors

5.3. Symptoms of CIN

5.4. Pathophysiology of CIN

5.5. Biomarkers of CIN

5.6. Diagnosis of CIN

5.6.1. Diagnostic algorithm of neutropenia

5.6.2. Diagnostic Guidelines of CIN

5.6.2.1. SEOM clinical practice guideline: management and prevention of febrile neutropenia in adults     with solid tumors (2018)

6. Treatment and Management

6.1. General approach used in the treatment of CIN

6.2. Guidelines for the Treatment of CIN

6.2.1. Management of chemotherapy-induced neutropenia in patients with cancer: 2019 guidelines of the Italian Medical Oncology Association (AIOM)

6.2.2. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. Methodology of Epidemiology

7.3. Total Number of Patients on Chemotherapy in the 7MM

7.4. Risk-specific Chemotherapy Patient Pool for CIN in the 7MM

7.5. Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the 7MM

7.6. Epidemiology of Chemotherapy Induced Neutropenia (CIN)

7.6.1. Breast Cancer

7.6.2. Lung Cancer

7.6.2.1. NSCLC

7.6.2.2. SCLC

7.6.3. Colorectal Cancer

7.6.4. Ovarian Cancer

7.6.5. Lymphoma

7.6.6. Multiple Myeloma

7.6.7. Acute Myeloid Leukemia

7.7. The United States

7.7.1. Total Number of Patients on Chemotherapy in the US

7.7.2. Risk-specific Chemotherapy Patient Pool for CIN in the US

7.7.3. Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the US

7.8. EU5

7.8.1. Germany

7.8.1.1. Total Number of Patients on Chemotherapy in Germany

7.8.1.2. Risk-specific Chemotherapy Patient Pool for CIN in Germany

7.8.1.3. Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Germany

7.8.2. France

7.8.2.1. Total Number of Patients on Chemotherapy in France

7.8.2.2. Risk-specific Chemotherapy Patient Pool for CIN in France

7.8.2.3. Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in France

7.8.3. Italy

7.8.3.1. Total Number of Patients on Chemotherapy in Italy

7.8.3.2. Risk-specific Chemotherapy Patient Pool for CIN in Italy

7.8.3.3. Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Italy

7.8.4. Spain

7.8.4.1. Total Number of Patients on Chemotherapy in Spain

7.8.4.2. Risk-specific Chemotherapy Patient Pool for CIN in Spain

7.8.4.3. Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Spain

7.8.5. The United Kingdom

7.8.5.1. Total Number of Patients on Chemotherapy in the United Kingdom

7.8.5.2. Risk-specific Chemotherapy Patient Pool for CIN in the United Kingdom

7.8.5.3. Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the United Kingdom

7.9. Japan

7.9.1. Total Number of Patients on Chemotherapy in Japan

7.9.2. Risk-specific Chemotherapy Patient Pool for CIN in Japan

7.9.3. Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Japan

8. Marketed Therapies

8.1. Neupogen (Filgrastim): Amgen

8.1.1. Product Description

8.1.2. Regulatory Milestones

8.1.3. Safety and Efficacy

8.1.4. Product Profile

8.2. Neulasta (pegfilgrastim): Amgen/Kyowa Hakko Kirin Co., Ltd.

8.2.1. Product Description

8.2.2. Regulatory Milestones

8.2.3. Safety and Efficacy

8.2.4. Product Profile

8.3. Lonquex (lipegfilgrastim): Teva B.V.

8.3.1. Product Description

8.3.2. Regulatory Milestones

8.3.3. Clinical Development

8.3.4. Clinical Trials Information

8.3.5. Safety and Efficacy

8.3.6. Product Profile

8.4. Cosela (trilaciclib): G1 Therapeutics

8.4.1. Product Description

8.4.2. Regulatory Milestones

8.4.3. Clinical Development

8.4.4. Clinical Trials Information

8.4.5. Safety and Efficacy

8.4.6. Product Profile

9. Emerging Therapies

9.1. Key Cross Competition

9.2. Rolontis (eflapegrastim): Spectrum Pharmaceuticals

9.2.1. Drug Description

9.2.2. Other Developmental Activities

9.2.3. Clinical Development

9.2.4. Clinical Trials Information

9.2.5. Safety and Efficacy

9.2.6. Product Profile

9.3. EC-18: Enzychem Lifesciences Corporation

9.3.1. Drug Description

9.3.2. Regulatory Milestones

9.3.3. Clinical Development

9.3.4. Clinical Trials Information

9.3.5. Product Profile

9.4. ALRN-6924: Aileron Therapeutics

9.4.1. Drug Description

9.4.2. Regulatory Milestones

9.4.3. Clinical Development

9.4.4. Clinical Trials Information

9.4.5. Safety and Efficacy

9.4.6. Product Profile

9.5. CLT-008/Romyelocel-L: Cellerant Therapeutics

9.5.1. Product Description

9.5.2. Other Developmental Activities

9.5.3. Clinical Development

9.5.4. Clinical Trials Information

9.5.5. Safety and Efficacy

9.5.6. Product Profile

9.6. Myelo001: Myelo therapeutics

9.6.1. Drug Description

9.6.2. Other Developmental Activities

9.6.3. Clinical Development

9.6.4. Clinical Trials Information

9.6.5. Safety and Efficacy

9.6.6. Product Profile

9.7. Plinabulin: BeyondSpring Pharmaceuticals

9.7.1. Drug Description

9.7.2. Other Developmental Activities

9.7.3. Clinical Development

9.7.4. Clinical Trials Information

9.7.5. Safety and Efficacy

9.7.6. Product Profile

9.8. F-627 (Ryzneuta): Evive Biotech

9.8.1. Drug Description

9.8.2. Other Developmental Activities

9.8.3. Clinical Development

9.8.4. Clinical Trials Information

9.8.5. Safety and Efficacy

9.8.6. Product Profile

10. Chemotherapy Induced Neutropenia (CIN): Seven Major Market Analysis

10.1. Key Findings

10.2. Methodology of Chemotherapy Induced Neutropenia (CIN) Market

10.3. Market Size of Chemotherapy Induced Neutropenia (CIN) in the 7MM

10.4. Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies

11. Market Outlook: 7MM

11.1. United States Market Size

11.1.1. Total Market Size of Chemotherapy Induced Neutropenia (CIN) in the United States

11.1.2. Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in the United States

11.2. EU-5 Market Size

11.2.1. Germany

11.2.1.1. Total Market size of Chemotherapy Induced Neutropenia (CIN) in Germany

11.2.1.2. Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in Germany

11.2.2. France

11.2.2.1. Total Market size of Chemotherapy Induced Neutropenia (CIN) in France

11.2.2.2. Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in France

11.2.3. Italy

11.2.3.1. Total Market size of Chemotherapy Induced Neutropenia (CIN) in Italy

11.2.3.2. Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in Italy

11.2.4. Spain

11.2.4.1. Total Market size of Chemotherapy Induced Neutropenia (CIN) in Spain

11.2.4.2. Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in Spain

11.2.5. United Kingdom

11.2.5.1. Total Market size of Chemotherapy Induced Neutropenia (CIN) in the United Kingdom

11.2.5.2. Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in the United Kingdom

11.3. Japan

11.3.1. Total Market size of Chemotherapy Induced Neutropenia (CIN) in Japan

11.3.2. Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in Japan

12. KOL Views

13. Market Drivers

14. Market Barriers

15. SWOT Analysis

16. Unmet Needs

17. Market Access and Reimbursement

18. Appendix

18.1. Bibliography

18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Chemotherapy Induced Neutropenia (CIN), Market, Epidemiology, and Key Events (2018–2030)

Table 2: MASCC Risk index and weights.

Table 3: Diagnostic/treatment recommendation

Table 4: The CISNE score

Table 5: Dosing and Administration of CSFs

Table 6: Total Number of Patients on Chemotherapy in the 7MM (2018–2030)

Table 7: Risk-specific Chemotherapy Patient Pool for CIN in the 7MM (2018–2030)

Table 8: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the 7MM (2018–2030)

Table 9: Total Number of Patients on Chemotherapy in the United States (2018–2030)

Table 10: Risk-specific Chemotherapy Patient Pool for CIN in the United States (2018–2030)

Table 11: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the United States (2018–2030)

Table 12: Total Number of Patients on Chemotherapy in Germany (2018–2030)

Table 13: Risk-specific Chemotherapy Patient Pool for CIN in Germany (2018–2030)

Table 14: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Germany (2018–2030)

Table 15: Total Number of Patients on Chemotherapy in France (2018–2030)

Table 16: Risk-specific Chemotherapy Patient Pool for CIN in France (2018–2030)

Table 17: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in France (2018–2030)

Table 18: Total Number of Patients on Chemotherapy in Italy (2018–2030)

Table 19: Risk-specific Chemotherapy Patient Pool for CIN in Italy (2018–2030)

Table 20: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Italy (2018–2030)

Table 21: Total Number of Patients on Chemotherapy in Spain (2018–2030)

Table 22: Risk-specific Chemotherapy Patient Pool for CIN in Spain (2018–2030)

Table 23: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Spain (2018–2030)

Table 24: Total Number of Patients on Chemotherapy in the United Kingdom (2018–2030)

Table 25: Risk-specific Chemotherapy Patient Pool for CIN in the United Kingdom (2018–2030)

Table 26: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the UK (2018–2030)

Table 27: Total Number of Patients on Chemotherapy in Japan (2018–2030)

Table 28: Risk-specific Chemotherapy Patient Pool for CIN in Japan (2018–2030)

Table 29: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Japan (2018–2030)

Table 30: Lonquex (lipegfilgrastim)

Table 31: Trilaciclib, Clinical Trial Description, 2021

Table 32: Comparison of emerging drugs under development

Table 33: Rolontis, Clinical Trial Description, 2021

Table 34: EC-18, Clinical Trial Description, 2021

Table 35: ALRN-6924, Clinical Trial Description, 2021

Table 36: CLT-008, Clinical Trial Description, 2021

Table 37: Myelo001, Clinical Trial Description, 2021

Table 38: Plinabulin, Clinical Trial Description, 2021

Table 39: F-627, Clinical Trial Description, 2021

Table 40: Seven Major Market Size of Chemotherapy Induced Neutropenia (CIN) in USD Million (2018–2030)

Table 41: Seven Major Market Size of Chemotherapy-Induced Neutropenia in USD Million (2018–2030)

Table 42: The United States Market Size of Chemotherapy Induced Neutropenia (CIN) in USD Million (2018–2030)

Table 43: The United States Market Size of Chemotherapy-Induced Neutropenia in USD Million (2018–2030)

Table 44: Germany Market Size of Chemotherapy Induced Neutropenia (CIN) in USD Million (2018–2030)

Table 45:  Germany Market Size of Chemotherapy-Induced Neutropenia in USD Million (2018–2030)

Table 46: France Market Size of Chemotherapy Induced Neutropenia (CIN) in USD Million (2018–2030)

Table 47: France Market Size of Chemotherapy-Induced Neutropenia in USD Million (2018–2030)

Table 48: Italy Market Size of Chemotherapy Induced Neutropenia (CIN) in USD Million (2018–2030)

Table 49: Italy Market Size of Chemotherapy-Induced Neutropenia in USD Million (2018–2030)

Table 50: Spain Market Size of Chemotherapy Induced Neutropenia (CIN) in USD Million (2018–2030)

Table 51: Spain Market Size of Chemotherapy-Induced Neutropenia in USD Million (2018–2030)

Table 52: The United Kingdom Market Size of Chemotherapy Induced Neutropenia (CIN) in USD Million (2018–2030)

Table 53: The United Kingdom Market Size of Chemotherapy-Induced Neutropenia in USD Million (2018–2030)

Table 54: Japan Market Size of Chemotherapy Induced Neutropenia (CIN) in USD Million (2018–2030)

Table 55: Japan Market Size of Chemotherapy-Induced Neutropenia in USD Million (2018–2030)

List of Figures

Figure 1: Onset of CIN and its consequences

Figure 2: CIN: Risks, Symptoms, and complications

Figure 3: Risk factors/Predictors for CIN and FN and its complications

Figure 4: Symptoms of CIN

Figure 5: Febrile Neutropenia: pathogenesis and clinical findings

Figure 6: Diagnostic approach to neutropenia (pediatric)

Figure 7: Diagnostic approach to neutropenia (adult)

Figure 8: Decision-making algorithm in febrile neutropenia

Figure 9: Recommendations for the prophylactic use of G-CSF based on chemotherapy regimens and patient risk factors

Figure 10: Primary prophylaxis flow chart. G-CSF: granulocyte colony-stimulating factor.

Figure 11: Secondary prophylaxis flow chart

Figure 12: Total Number of Patients on Chemotherapy in the 7MM (2018–2030)

Figure 13: Risk-specific Chemotherapy Patient Pool for CIN in the 7MM (2018–2030)

Figure 14: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the 7MM (2018–2030)

Figure 15: Global Heat Map of All Cancers

Figure 16: Total Number of Patients on Chemotherapy in the United States (2018–2030)

Figure 17: Risk-specific Chemotherapy Patient Pool for CIN in the United States (2018–2030)

Figure 18: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the United States (2018–2030)

Figure 19: Total Number of Patients on Chemotherapy in Germany (2018–2030)

Figure 20: Risk-specific Chemotherapy Patient Pool for CIN in Germany (2018–2030)

Figure 21: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Germany (2018–2030)

Figure 22: Total Number of Patients on Chemotherapy in France (2018–2030)

Figure 23: Risk-specific Chemotherapy Patient Pool for CIN in France (2018–2030)

Figure 24: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in France (2018–2030)

Figure 25: Total Number of Patients on Chemotherapy in Italy (2018–2030)

Figure 26: Risk-specific Chemotherapy Patient Pool for CIN in Italy (2018–2030)

Figure 27: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Italy (2018–2030)

Figure 28: Total Number of Patients on Chemotherapy in Spain (2018–2030)

Figure 29: Risk-specific Chemotherapy Patient Pool for CIN in Spain (2018–2030)

Figure 30: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Spain (2018–2030)

Figure 31: Total Number of Patients on Chemotherapy in the United Kingdom (2018–2030)

Figure 32: Risk-specific Chemotherapy Patient Pool for CIN in the United Kingdom (2018–2030)

Figure 33: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in the United Kingdom (2018–2030)

Figure 34: Total Number of Patients on Chemotherapy in Japan (2018–2030)

Figure 35: Risk-specific Chemotherapy Patient Pool for CIN in Japan (2018–2030)

Figure 36: Total Incident Cases of Chemotherapy Induced Neutropenia (CIN) by Cancer Type in Japan (2018–2030)

Figure 37: Seven Major Market Size of Chemotherapy Induced Neutropenia (CIN) in USD Million (2018–2030)

Figure 38: Seven Major Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD Million (2018–2030)

Figure 39: Market Size of Chemotherapy-Induced Neutropenia in the United States, USD Million (2018–2030)

Figure 40: The United States Market Size of Chemotherapy-Induced Neutropenia by Therapies in USD Million (2018–2030)

Figure 41: Market Size of Chemotherapy Induced Neutropenia (CIN) in Germany, USD Million (2018–2030)

Figure 42: Germany Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD Million (2018–2030)

Figure 43: Market Size of Chemotherapy Induced Neutropenia (CIN) in France, USD Million (2018–2030)

Figure 44: France Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD Million (2018–2030)

Figure 45: Market Size of Chemotherapy Induced Neutropenia (CIN) in Italy, USD Million (2018–2030)

Figure 46: Italy Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD Million (2018–2030)

Figure 47: Market Size of Chemotherapy Induced Neutropenia (CIN) in Spain, USD Million (2018–2030)

Figure 48: Spain Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD Million (2018–2030)

Figure 49: Market Size of Chemotherapy Induced Neutropenia (CIN) in the UK, USD Million (2018–2030)

Figure 50: The UK Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD Million (2018–2030)

Figure 51: Market Size of Chemotherapy Induced Neutropenia (CIN) in Japan, USD Million (2018–2030)

Figure 52: Japan Market Size of Chemotherapy Induced Neutropenia (CIN) by Therapies in USD Million (2018–2030)

Figure 53: Market Drivers

Figure 54: Market Barriers

Figure 55: SWOT Analysis

Figure 56: Unmet Needs

• Amgen

• Amgen/Kyowa Hakko Kirin Co., Ltd.

• Teva B.V.

• G1 Therapeutics

• Spectrum Pharmaceuticals

• Enzychem Lifesciences Corporation

• Aileron Therapeutics

• Cellerant Therapeutics

• Myelo therapeutics

• BeyondSpring Pharmaceuticals

• Evive Biotech

  • Tags:
  • Chemotherapy Induced Neutropenia (C...
  • Chemotherapy Induced Neutropenia m...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...
  • Chemotherapy Induced Neutropenia (...

Forward to Friend

Need A Quote